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ABSTRACT
The skin barrier defect is the first step in the development of atopic 
dermatitis (AD). Various therapeutic guidelines recommend using 
moisturizers to maintain the skin barrier and the prevention of AD. 
The use of a moisturizer in the form of barrier cream is considered to 
improve the skin barrier. However, this dosage form is occlusion and has 
an oily texture, resulting in patient noncompliance with therapy. Various 
techniques were developed to improve patient compliance in applying 
topical preparations, one of which is by developing nanotechnology. 
Recent studies aim to develop nanoformula preparations because they 
can help deliver drug molecules to specific targets with minimize side 
effects. The application of nanoformula moisturizer is promising in the 
management of AD because of its ability to reduce water loss and prevent 
irritation and produce formulations with a thinner texture to increase 
therapeutic compliance in AD patients.
ABSTRAK
Kerusakan sawar kulit merupakan langkah awal perkembangan dermatitis 
atopik (DA). Berbagai pedoman terapi merekomendasikan pemakaian 
pelembap untuk pemeliharaan sawar kulit dan pencegahan terjadinya 
DA. Pemakaian pelembap dalam bentuk barrier cream dianggap dapat 
memperbaiki sawar kulit. Akan tetapi, bentuk sediaan ini bersifat oklusi 
dan dengan tekstur berminyak, yang berakibat pada ketidakpatuhan 
pasien terhadap pengobatan. Berbagai teknik dikembangkan untuk 
meningkatkan kepatuhan pasien dalam mengaplikasikan sediaan 
topikal, salah satunya dengan pengembangan nanoteknologi. Penelitian 
terbaru ini lebih ditujukan pada pengembangan sediaan nanoformula 
karena dapat membantu penghantaran molekul obat ke target spesifik 
dengan efek samping minimal. Aplikasi pelembap nanoformula bersifat 
menjanjikan pada tatalaksana DA karena karena kemampuannya untuk 
meminimalkan kehilangan air dan mencegah iritasi serta menghasilkan 
formulasi dengan tekstur yang lebih tipis sehingga dapat meningkatkan 
kepatuhan pengobatan pasien DA.
INTRODUCTION
Atopic dermatitis (AD) is an 
inflammatory disease of the skin 
characterized by itchy, chronic, and 
residif. Since 1960, there has been a 
reported increase of AD prevalence 
more than tripled. Atopic dermatitis 
occurs in 20% of children, generally in 
the first year of life and 1-3% in adults 
worldwide. Atopic dermatitis can affect 
patients and their families’ quality of life 
and social and economic problems. Some 
studies report the incidence of anxiety, 
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depression, and other psychological 
issues in AD patients.
Topical corticosteroids are still the 
primary treatment of AD.1-4 The provision 
of topical therapy in the treatment of 
skin diseases can reduce the occurrence 
of side effects due to parenteral and oral 
therapy administration because it can 
reduce the metabolism of drugs through 
the liver.5 Topical corticosteroids can be 
used only for a short time and in limited 
skin lesions because they can cause 
undesirable side effects.1–5 Besides, the 
incidence of topical steroid withdrawal 
and topical corticosteroid addiction has 
been widely reported on social media.6,7 
This condition raises fears of the use of 
topical corticosteroids (corticosteroid 
phobia), which occurs in about 40% of 
patients with dermatology and 73% in 
their parents.8 Corticosteroid phobia 
results in reduced adherence and causes 
therapy failure.6-8
Various therapeutic guidelines 
consistently recommend using 
moisturizers to maintain the skin barrier 
and the prevention of AD. The use of a 
moisturizer is reported to reduce the use 
of topical steroids.1 Topical preparations’ 
clinical effectiveness is generally 
observed in its mechanism of action and 
its ability to cross the skin’s protective 
barrier.5 Topical drug application has 
limitations because of its low drug 
absorption in the skin barrier, especially 
in the stratum corneum.9,10  In this review 
article, a moisturizing application in the 
form of a nanoformula in AD will be 
further examined.
DISCUSSION
Skin barriers defects in atopic 
dermatitis
The skin is the largest organ (covering 
10% of body weight), which protects 
against the external environment.11 The 
skin consists of layers of the epidermis, 
dermis, and subcutaneous fat.12 The 
epidermis can act as an inside-out barrier 
that minimizes transepidermal water 
loss and outside-in barriers that prevent 
the invasion of infectious agents and 
toxic substances.11 The physical barrier 
function of the skin depends primarily on 
the integrity of the stratum corneum.13-15 
The skin barrier defect is considered as 
an initial step in developing AD.15 Genetic 
and environmental factors influence 
the skin barrier defect in AD. Some 
abnormalities in the epidermal barrier 
that play a role in the pathophysiology of 
AD include defects in filaggrin, increased 
serine protease activity, and decreased 
levels of ceramides and stratum corneum 
lipids.16-18 These factors interact with 
each other, which can modify the skin 
barrier.15
Filaggrin defects in atopic dermatitis
Filaggrin (filament aggregating 
protein) is a unique filament related 
protein that binds to keratin fibers in 
epithelial cells.19 Filaggrin is an essential 
epidermal protein in the formation of 
corneocytes-intracellular metabolites 
that contribute to the hydration of the 
stratum corneum and skin acidity.20,21 
In humans, profilaggrin is encoded 
by the filaggrin gene in the epidermal 
differentiation complex (EDC) on 
chromosome 1q21.16,19
In stratum granulosum, filaggrin is 
produced as profilaggrin and stored in 
keratohyalin granules. In the transition 
from stratum granulosum to stratum 
corneum, filaggrin is converted into 
filaggrin monomers by proteases such 
as CAP1/Prss8 and SASPase/ASPRV1.16,22 
Filaggrin monomers bind keratin 
filaments to form a filament-matrix 
complex, which is also bound to cornified 
envelopes (CE).16 In the upper layers of the 
stratum corneum, filaggrin is separated 
from the keratin filaments. Filaggrin 
monomers are degraded to amino acids 
(glutamine, arginine, and histidine), 
which are then converted to urocanic 
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acid (UCA) and pyrrolidine carboxylic 
acid (PCA), mediated by protein caspase 
14, calpain 1, and bleomycin hydrolase. 
Urocanic acid plays a vital role as an 
ultraviolet absorbing chromophore in 
the stratum corneum and maintaining 
skin acidity (pH). Pyrrolidine carboxylic 
acid is a natural moisturizing factor 
(NMF) element responsible for holding 
water in the stratum corneum.22
A defect in filaggrin can reduce 
NMF levels, which results in decreased 
hydration and an increase in skin pH.23 
Filaggrin is essential in maintaining 
epidermal homeostasis. Impaired 
filaggrin function is a predisposing 
factor for AD.17,24 Filaggrin expression in 
AD patients is regulated by T helper (Th)-
2 cytokines, and filaggrin proteolysis 
is accelerated after exposure to low 
humidity or irritant material to the 
skin.21
Serin protease defects in atopic 
dermatitis
In the stratum corneum of the 
skin, there are three protease families, 
including serine specific epidermal 
kallikrein 5 (stratum corneum tryptic 
enzyme/SCTE) and kallikrein 7 (stratum 
corneum chymotryptic enzyme/SCCE); 
cysteine protease (cathepsin C, L, and V); 
and aspartate proteases (cathepsin D). 
Protease is an enzyme that hydrolyzes 
peptide bonds and plays a role in signaling 
important molecules in mammals’ 
homeostatic regulation and various 
pathological conditions.25 Protease 
plays a role in the pathogenesis of AD 
through filaggrin formation, regulation 
of inflammation, and itching.18,25
Protease inhibitors regulate 
endogenous skin proteases, which are 
essential in maintaining skin barrier 
permeability, and homeostasis.18 
Protease inhibitors control the 
function of exogenous and endogenous 
proteases.26  Serine protease inhibitors 
in the skin function to regulate 
proteolytic activity to prevent excessive 
serine protease cascades and maintain 
skin barrier permeability homeostasis. 
Lymphoepithelial Kazal-type-related 
inhibitors (LEKTI)-1 are serine protease 
inhibitors thought to have a major role 
in the stratum corneum. It is encoded by 
the Kazal-type 5 serine protease inhibitor 
gene (SPINK5), which can inhibit trypsin, 
plasmin, subtilisin A, cathepsin G, and 
human neutrophil elastase.25
Protease plays a role in the 
pathogenesis of AD through filaggrin 
formation, regulation of inflammation, 
and itching.18,25 In AD, there is an increase 
in serine protease activity, which can be 
caused by changes in skin pH and genetic 
polymorphisms in the enzyme serine 
protease or serine protease inhibitors. 
Serine protease enzymes work optimally 
at neutral or basic pH so that an increase 
in skin pH increases serine protease 
activity.27 Increases in the enzymes of 
tryptase and chymotriptase in patients 
with AD indicate an imbalance between 
proteases and protease inhibitors, which 
causes inflammation.28
Ceramide defects and stratum 
corneum lipids in atopic dermatitis
In AD, there is a decrease in total 
and ceramide lipid levels, changes in 
the ceramide subfraction, and possible 
disruption in the activity of enzymes 
that modulate lipids in skin barrier 
permeability.27 Ceramides are the 
main lipid component in the stratum 
corneum, consisting of 30-40% of total 
lipid weight.29 Ceramides are the main 
water retaining molecules in the stratum 
corneum. The reduction of the AD 
patients’ ceramide level was obtained in 
lesions and skin without skin lesions.30
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Immunological mechanisms of skin 
barrier defect in atopic dermatitis
Defects in the skin barrier cause 
an increase in trans-epidermal water 
loss (TEWL), which facilitates allergens’ 
entry so that allergic initiation and 
sensitization or exacerbation of 
inflammation in AD can occur.17,24 An 
increase in TEWL causes an increase in 
pH that can activate serine proteases.24 
The biological activity of proteases is 
mediated by the activation of protease-
activated receptors (PAR).18,25
Increased serine protease activity 
will activate PAR2 in stratum granulosum 
keratinocyte cells, causing a decrease 
in lamellar body secretions that are 
important in maintaining skin barrier 
permeability homeostasis overcome 
skin barrier recovery.25,26,31 Activation of 
PAR2 can act as a positive regulator of 
skin barrier permeability improvement, 
namely by accelerating cornification, 
which then induces corneocyte cell 
formation.25
The stimulation of PAR2 in 
keratinocyte cells will increase the 
secretion of interleukin (IL)-6 and 
granulocyte macrophage-colony 
stimulating factor (GM-CSF). Activation 
of PAR2 in keratinocytes increases IL-8/
CXCL8 secretion, which will cause the 
release of granulocytes and T cells.25 
Activation of PAR2 in keratinocytes 
will also induce thymic stromal 
lymphopoietin (TSLP) release and 
contribute to allergic inflammation.24,32,33
Increased expression of TSLP is a vital 
pathogenesis factor in AD development. 
Thymic stromal lymphopoietin 
causes migration of Langerhans cells, 
maturation, activation, and polarization 
of dendritic cells, which trigger Th-2 cell 
responses to AD skin lesions.34 Thymic 
stromal lymphopoietin activates mature 
dendritic cells and Langerhans cells 
by increasing the expression of CD83, 
CD86, OX40 ligand (OX40L), and major 
class II histocompatibility complex 
(MHC), which will cause expansion and 
differentiation of T cells. Dendritic TSLP 
cells induce naive T cells to become pro-
allergic T cells with increased IL-4, IL-5, 
IL-13, and tumor necrosis factor (TNF) –α 
and decreased IL-10.35
Disorders of the skin barrier 
also cause an increase in IL-1 from 
keratinocytes, which activate vascular 
endothelium to induce adhesion 
molecules’ expression and cause skin 
inflammation.17 Dysregulation of skin 
homeostasis causes direct or indirect 
stimulation of sensory nerve endings 
that induces itching.24 Schema of the 
relationship between the skin barrier 
defect with the immune response to AD 
can be seen in FIGURE 1.
FIGURE 1. Relationship between skin barrier defects and immune 
response in DA. It was modified from reference.36
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Moisturizer in atopic dermatitis
Various therapeutic guidelines 
consistently recommend using 
moisturizers to maintain the skin 
barrier and prevent AD.1 Atopic 
dermatitis patients are characterized 
by decreased skin barrier function and 
dry skin (xerosis), facilitating the entry 
of pathogens, irritants, and allergens.2,37 
Some studies show that moisturizer 
application can reduce the use of 
topical corticosteroids. Moisturizers are 
reported can improve AD complaints and 
are well tolerated in children as young as 
six months.1 The use of a moisturizer is 
recommended as monotherapy in mild 
AD cases, should be applied twice a day 
on the whole body both in the condition 
of disease and no disease. Long-term use 
of a moisturizer in AD patients aged 2-6 
years decreased xerosis and AD scores 
better than the control group without 
significant side effects.38 
The use of a moisturizer in the form 
of a barrier cream that is a form of water-
in-oil (W/O) emulsion and oil-in-water 
(O/W) emulsion is considered to improve 
the skin barrier function in inflammatory 
conditions by causing occlusion and 
change allergens and other irritant 
molecules. However, patients’ adherence 
to these preparations is influenced by 
their cosmetic properties, where the 
preparations are very occlusive tend 
to have a glossy or partially blurry 
appearance and oily texture. To increase 
cosmetics’ attractiveness, more elegant 
textures, and obtain additional benefits, 
nanomaterial use in barrier cream 
formulations has been developed.39
Dermatopharmacokinetics
Dermatopharmacokinetics describes 
the pharmacokinetics of topical drugs 
on the stratum corneum with their 
pharmacodynamic effects.9 Drug 
absorption in the skin depends on 
drug interactions with intracellular 
lipid bilayers, drug interactions with 
keratinocytes, and drug interactions with 
permeation enhancers, which cause a 
reversible dissolution of the skin barrier 
so that the drug can penetrate the skin.10
One limitation of topical drug 
application is the low absorption of 
the drug on the skin barrier, especially 
on the stratum corneum.9,10 Strategies 
to increase the absorption of drugs to 
the skin are choosing a vehicle system, 
adding substances that enhance 
absorption (permeation enhancers), 
choosing a new drug delivery system 
(drug carrier systems), and transdermal 
patches.10 Recent studies have focused 
more on the selection of nanoparticle 
drug dosage forms.40
Nanoparticles are particulate 
dispersions or solid particles with sizes 
in the range of 10 to 1000 nm. The drug 
is dissolved, encapsulated, or attached 
to a nanoparticle matrix. The primary 
purpose of nanoparticles as a drug 
delivery system is to control particle 
size, drug surface, the release of active 
pharmaceutical ingredients to reach the 
specific site of action of the drug, and 
improve drug stability.41 Properties are 
affecting the penetration of nanoparticles 
through the stratum corneum, as well as 
the potential for deposition in the skin, 
appendage, and deeper layers of the skin, 
including size, shape, charge properties, 
surface properties such as coatings or 
functional groups, aggregation status on 
surface properties.42
Topical drug delivery with nanosystem
At present, nanosystems have been 
developed to help deliver drug molecules 
to specific drug targets and minimize 
side effects.43 The forms of nanosystems 
include microemulsions (MEs), 
nanoemulsions (NEs), nanoparticles with 
various compositions including solid lipid 
nanoparticles (SNLs), nanostructured 
lipid carriers (NLCs), liposomes, and 
vesicles.42,44,45 Nanosystems can provide 
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significant advantages in hydrophobic 
molecular formulations, increasing their 
solubility and bioavailability of drugs.45
Several factors influence nanosystem 
drugs’ release, namely particle size, lipid 
matrix, surfactants, drug loading, and 
medication type.46 The size and shape 
of drug particles affect drug release, 
physical stability, and cellular absorption 
of drug nanoparticles. In contrast, the 
attachment of nanoparticles to cell 
membranes is affected by the surface 
particle charge. Nanoparticles show 
high affinity in cell membranes, mainly 
due to their electrostatic interactions. 
Formulations of nanoparticles with 
different surface properties can influence 
cellular uptake and intracellular 
distribution. It is possible to localize 
nanoparticles to specific intracellular 
targets (lysosomes, mitochondria, and 
cytoplasm) by modifying their surface 
charges.9 Vehicle components such as 
oil, surfactants, and alcohol interact 
with the stratum corneum, which affects 
the distribution and performance of 
nanoparticle drugs on the skin.47 The 
topical drug absorption nanosystem 
scheme is listed in FIGURE 2.
FIGURE 2. The nanosystem scheme determines the absorption of topical drugs 
and potential penetration routes. It was modified from reference.42
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Nanoemulsion
Nanoemulsion is a water and oil 
phase dispersion that is stabilized 
by surfactants.42 Nanoemulsion is 
an ultrafine emulsion because of the 
formation of droplets in the submicron 
range. Nanoemulsion droplet sizes 
generally range between 200-300 nm, 
smaller than macroemulsion droplet 
sizes ranging from 1-100 µm. Small 
droplet size causes NE to be stable, not 
experience creaming, sedimentation, 
flocculation, and coalescence allows 
effective transportation of material to 
the skin.42,48
Nanoemulsion application to the 
skin has several advantages, including 
the small size of the droplets allowing it 
to be stored evenly on the skin, suitable 
for delivering active ingredients through 
the skin.42 The small size of the droplets 
causes the product to be transparent 
so that the NE appearance does not 
change by adding the oil phase.49 
Nanoemulsion is mainly used in drugs 
with low absorption by increasing drug 
absorption through the skin, better drug 
retention time in the target area, which 
leads to fewer side effects.50
Nanoemulsion can increase drug 
penetration in the skin through several 
mechanisms. First, nanoemulsion 
provides a high dissolving capacity for 
lipophilic and hydrophilic compounds, 
increasing the loading capacity and 
dosage formulation application. Second, 
nanoemulsion has a large surface area 
and good skin contact, coupled with 
occlusive properties that allow good 
surface contact with the surface of the 
stratum corneum. Third, The oil and 
surfactant components in NE directly 
increase the permeation effect on the 
stratum corneum lipids structure.42
The nanoemulsion system consists 
of oil, water, one or more surfactant 
materials, O/W or W/O. The aqueous 
phase can contain pharmaceutically 
active ingredients, cosmetics, or 
preservatives, which are hydrophilic. 
In contrast, the oil phase contains 
mineral oils, silicone oils, plant oils, 
fatty acid esters, and lipophilic active 
ingredients. The addition of surfactants 
such as disodium stearoyl glutamate, 
sucrose alkyl ester, sorbitan alkyl 
ester, and dimethicone copolyol form 
stable dispersion formations that 
guarantee storage time. The use of NE 
in cosmetics is generally in the form of 
O/W containing 10-20% oil and stabilized 
with an emulsion material of 0.5-2%.44 
The limitation of NE application to the 
skin is discomfort when used because 
NE has a low viscosity and spreadability. 
To overcome this problem, the NE is 
combining with a gel system known as 
nanoemulgel.50
Nanoemulgel
Nanoemulgel acts as a drug reservoir 
that controls the release of drugs to the 
skin. The ability of nanoemulgel to seep 
into the skin and release therapeutic 
agents is influenced by the drug’s 
affinity to diffuse out of the vehicle 
and penetrate the skin barrier. The 
addition of emulsifiers and thickening 
agents results in better drug stability, 
absorption, and viscosity, suitable for 
topical drug delivery. Nanoemulgel on 
intact skin will release oil droplets that act 
as lipophilic drug carriers. Nanoemulgel 
has excellent adhesion properties on 
the skin, high dissolving capacity, thus 
causing a more significant concentration 
gradient towards the skin, which will 
affect further drug penetration in the 
skin. The nanoemulgel dosage form also 
improves patient compliance because it 
is not sticky and is easier to apply than 
other topical preparations on the skin.50
Nanoformula moisturizer in atopic 
dermatitis
Nanocarriers like liposomes, NEs, 
SLNs, and niosomes are extensively 
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added to the moisturizers as they form 
a thin film of humectants and retain 
the moisture for a prolonged span.51 
In cosmetics formulation, NEs provide 
rapid penetration and active transport of 
active ingredients and hydration to the 
skin.52 The nanoformula moisturizers 
are superior to conventional creams to 
minimize water loss, prevent irritation, 
and produce a thinner texture.39
Clinical trials in humans have found 
that combined SLN on O/W emulsions 
can significantly increase hydration than 
conventional moisturizers.39,53 After four 
weeks of application periods, there were 
significant changes in skin hydration for 
both formulations. The SLN-enriched 
cream was significantly more effective 
than the conventional cream (+24% 
for the cream vs. +31% for the SLN 
cream).53 The addition of nanomaterials 
to moisturizing preparations provides 
cosmetic benefits. Kato et al.39 stated that 
fullerene nano preparation dissolved 
in squalene minimizes water loss 
and significantly improves wrinkles’ 
appearance. A study by Berardesca et al.54 
showed that eight weeks of application 
of topical skin lipid mixture containing 
ceramide-3 and nanoparticles alone, or 
combined with topical corticosteroids, 
will improve the skin physiology, barrier 
properties, and clinical symptoms. in AD 
patients.54,55 This study indicated that the 
nanoparticles’ optimized lipid mixture 
could improve skin barrier repair and 
improve various skin diseases with the 
damaged skin barrier.54
Bernadi et al.56 concluded that rice 
bran oil nanoemulsion could serve as an 
alternative treatment for AD and psoriasis 
because it showed a stable formulation, 
low potential irritation, improved skin 
moisturizer, and maintained normal skin 
pH value. The rice bran oil application 
significantly increases the skin hydration 
with moisturizing variance by about 
38% in normal skin volunteers and 30% 
in AD volunteers. This study showed a 
satisfactory result because a high-quality 
commercial moisturizer only increased 
skin hydration 20% after 14 days of 
application.56
Nasrollahi et al.57 have compared the 
efficacy and safety of a w/o emulsions 
containing 1.5% linoleic acid and w/o 
emulsion containing 5% urea in AD 
patients. Both formulations significantly 
improved the epidermal barrier function 
and alleviate AD symptoms. Based on 
previous studies, it can be concluded 
that the application of nanoformula 
moisturizer is promising in the 
management of AD because of its ability 
to minimize water loss and prevent 
irritation and product formulations with 
a thinner texture to increase therapeutic 
compliance in AD patients.
CONCLUSION
There are recommendations for 
using moisturizers to maintenance skin 
barrier and prevention of AD. The use 
of a moisturizer in the form of a barrier 
cream, a form of water emulsion in oil 
or oil emulsion in water, is considered 
to improve the skin barrier function in 
inflammatory conditions by causing 
occlusion and changing allergens and 
other irritant molecules. Barrier cream 
is occlusive, with an oily texture, which 
results in patient noncompliance with 
therapy. The application of nanoformula 
moisturizer is promising in the 
management of AD because of its ability 
to minimize water loss and prevent 
irritation and produce formulations with 
a thinner texture to increase therapeutic 
compliance in AD patients.
ACKNOWLEDGEMENT
The authors have no conflicts of 
interest to declare.
REFERENCES
1. Correa MCM, Nebus J. Management 
of patients with atopic dermatitis: the 
214
Suryawati N, et al., Innovative approach of nanoformula...
role of emollient therapy. Dermatol 
Res Pract 2012; 2012:836931.
https://doi.org/10.1155/2012/836931
2. Leung D, Lawrence F, Mark B. Atopic 
Dermatitis (Atopic Eczema). In: 
Goldsmith L, Katz S, Gilchrest B, 
Paller A, Leffell D, Wolff K, editors. 
Fitzpatrick’s Dermatology in General 
Medicine. 8th ed. New York: McGraw 
Hill, 2012. 165-82. 
3. Choi J-H, Song Y-S, Lee H-J, 
Hong J-W, Kim G-C. Inhibition 
of inflammatory reactions in 
2,4-dinitrochlorobenzene induced 
Nc/Nga atopic dermatitis mice by 
non-thermal plasma. Sci Rep 2016; 
6:27376.
https://doi.org/10.1038/srep27376
4. Martel BC, Lovato P, Bäumer W, 
Olivry T. Translational animal 
models of atopic dermatitis for 
preclinical studies. Yale J Biol Med 
2017; 90(3):389-402.
5. Kakkar V, Saini K. Scope of nano 
delivery for atopic dermatitis. Ann 
Pharmacol Pharm 2017; 2(7):1-4. 
6. Hajar T, Leshem YA, Hanifin JM, 
Nedorost ST, Lio PA, Paller AS, et 
al. A systematic review of topical 
corticosteroid withdrawal (“steroid 
addiction”) in patients with atopic 
dermatitis and other dermatoses. J 
Am Acad Dermatol 2015; 72(3):541-9.
https://doi.org/10.1016/j.jaad.2014.11.024
7. Sheary B. Steroid withdrawal 
effects following long-term topical 
corticosteroid use. Dermatitis 2018; 
29(4):213-8.
h t t p s : / / d o i . o r g / 1 0 . 1 0 9 7 /
DER.0000000000000387
8. Smith SD, Stephens AM, Werren 
JC, Fischer GO. Treatment failure 
in atopic dermatitis as a result of 
parental health belief. Med J Aust 
2013; 199(7):467-9.
https://doi.org/10.5694/mja12.10802
9. Uchechi O, Ogbonna JDN, Attama 
AA. Nanoparticles for Dermal and 
Transdermal Drug Delivery. In: 
Sezer AD, editor. Application of 
Nanotechnology in Drug Delivery 





[cited 2019 Sep 8].
10. Shukla T, Upmanyu N, Agrawal 
M, Saraf S, Saraf S, Alexander 
A. Biomedical applications of 
microemulsion through dermal 
and transdermal route. Biomed 
Pharmacother 2018; 108:1477-94.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
biopha.2018.10.021
11. Zhang Y, Tu C, Wang S, Xiao S. 
Expression of skin barrier protein 
filaggrin in skin diseases without 
atopic dermatitis. J Biosci Med 2018; 
06(01):101-12.
https://doi.org/10.4236/jbm.2018.61009
12. Dainichi T, Kitoh A, Otsuka A, 
Nakajima S, Nomura T, Kaplan 
DH, et al. The epithelial immune 
microenvironment (EIME) in 




13. Lin T-K, Zhong L, Santiago J. Anti-
inflammatory and skin barrier 
repair effects of topical application 
of some plant oils. Int J Mol Sci 2017; 
19(1):70.
https://doi.org/10.3390/ijms19010070
14. Egawa G, Kabashima K. Barrier 
dysfunction in the skin allergy. 
Allergol Int 2018; 67(1):3-11.
https://doi.org/10.1016/j.alit.2017.10.002
15. Kim BE, Leung DYM. Significance of 
skin barrier dysfunction in atopic 
dermatitis. Allergy Asthma Immunol 
Res 2018; 10(3):207-15.
https://doi.org/10.4168/aair.2018.10.3.207
16. Levin J, Friedlander SF, Rosso JQD. 
Atopic dermatitis and the stratum 
corneum. Part 1: the role of filaggrin 
in the stratum corneum barrier and 
atopic skin. J Clin Aesthet Dermatol 
2013; 6(10):16-22.
215
J Med Sci, Volume 53, Number 2, 2021 April: 206-217
17. Kim JE, Kim JS, Cho DH, Park HJ. 
Molecular mechanisms of cutaneous 
inflammatory disorder: atopic 
dermatitis. Int J Mol Sci 2016; 
17(8):1234.
https://doi.org/10.3390/ijms17081234 
18. Czarnowicki T, Krueger JG, Yassky 
EG. Novel concepts of prevention 
and treatment of atopic dermatitis 
through barrier and immune 
manipulations with implications 
for the atopic march. J Allergy Clin 
Immunol 2017; 139(6):1723-34.
https://doi.org/10.1016/j.jaci.2017.04.004 
19. Sehgal V. The impact of microanatomy 
and changing physiology of stratum 
corneum, the skin barrier, on 
evolution of atopic dermatitis. J 
Dermatitis 2019; 4(1):1-4.
ht tps : / /doi .org/10.35248/2684-
1436.19.4.116 
20. Darlenski R, Kazandjieva J, Tsankov N. 
Skin barrier function: morphological 
basis and regulatory mechanisms. J 
Clin Med 2011; 4:36-45. 
21. Thyssen JP, Kezic S. Causes of 
epidermal filaggrin reduction and 
their role in the pathogenesis of 
atopic dermatitis. J Allergy Clin 
Immunol 2014; 134(4):792-9.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
jaci.2014.06.014 
22. Egawa G, Kabashima K. Multifactorial 
skin barrier deficiency and atopic 
dermatitis: Essential topics to 
prevent the atopic march. J Allergy 
Clin Immunol 2016; 138(2):350-8.
https://doi.org/10.1016/j.jaci.2016.06.002 
23. Clausen ML, Agner T, Thomsen SF. 
Skin barrier dysfunction and the 
atopic march. Curr Treat Options 
Allergy 2015; 2(3):218-27. 
24. Mollanazar NK, Smith PK, Yosipovitch 
G. Mediators of chronic pruritus in 
atopic dermatitis: getting the itch 




25. Lee K-S, Jeong E-S, Heo S-H, Seo 
J-H, Jeong D-G, Choi Y-K. A novel 
model for human atopic dermatitis: 
application of repeated DNCB patch 
in BALB/c mice, in comparison with 
NC/Nga mice. Lab Anim Res 2010; 
26(1):95.
https://doi.org/10.5625/lar.2010.26.1.95
26. Takai T, Ikeda S. Barrier Dysfunction 
caused by environmental proteases 
in the pathogenesis of allergic 
diseases. Allergol Int 2011; 60(1):25-35.
h t t p s : / / d o i . o r g / 1 0 . 2 3 3 2 /
allergolint.10-RAI-0273 
27. Levin J, Friedlander SF, Rosso JQD. 
Atopic Dermatitis and the stratum 
corneum. Part 2: Other structural 
and functional characteristics of the 
stratum corneum barrier in atopic 
skin. J Clin Aesthet Dermatol 2013; 
6(11):49-54. 
28. Egawa G, Weninger W. Pathogenesis 
of atopic dermatitis: A short review. 




2015 Oct 20 [cited 2018 Jul 5];1(1).
29. Kubo A, Amagai M. Skin barrier. In: 
Kang S, Amagai M, Bruckner A, Enk 
A, Margolis D, McMichael A, et al., 
editors. Fitzpatrick’s Dermatology. 
9th ed. New York: Mc Graw Hill 
Education; 2019. 206-31. 
30. Novak N, Bieber T. The pathogenesis 
of atopic dermatitis. In: Reitamo 
S, Luger T, Steinhoff M, editors. 
Textbook of Atopic Dermatitis. 1st ed. 
London: CRC Press; 2008. 25-33. 
31. Maintz L, Novak N. Modifications of 
the innate immune system in atopic 
dermatitis. J Innate Immun 2011; 
3(2):131-41.
https://doi.org/10.1159/000323963 
32. Elmariah SB, Lerner EA. The missing 
link between itch and inflammation 
in atopic dermatitis. Cell 2013; 
155(2):267-9.
https://doi.org/10.1016/j.cell.2013.09.038 
33. Akiyama T, Lerner EA, Carstens 
E. Protease-activated receptors 
216
Suryawati N, et al., Innovative approach of nanoformula...
and itch. In: Cowan A, Yosipovitch 
G, editors. Pharmacology of Itch 
[Internet]. Berlin, Heidelberg: 
Springer Berlin Heidelberg. 
h t t p : / / l i n k . s p r i n g e r .
com/10.1007/978-3-662-44605-
8_13,2015 [cited 2018 Nov 6].p. 219-
35.
34. Cianferoni A, Spergel J. The 
importance of TSLP in allergic 
disease and its role as a potential 
therapeutic target. Expert Rev Clin 
Immunol 2014; 10(11):1463-74.
https: / /doi .org/10.1586/174466
6X.2014.967684
35. Wang J, Xing F. Human TSLP-
educated DCs. Cell Mol Immunol 
2008; 5(2):99-106.
https://doi.org/10.1038/cmi.2008.12 
36. Rerknimitr P, Otsuka A, Nakashima C, 
Kabashima K. The etiopathogenesis of 
atopic dermatitis: barrier disruption, 
immunological derangement, and 
pruritus. Inflamm Regen 2017; 37:14.
https://doi.org/10.1186/s41232-017-
0044-7 
37. Berke R, Sing A, Guralnick M. Atopic 
dermatitis: an overview. Am Fam 
Physician 2012; 86(1):35-42. 
38. Raone B, Ravaioli G, Dika E, Neri 
E, Gurioli C, Patrici A. The use of 
emollients for atopic eczema. Austin 
J Allergy 2015; 2(1):1-11. 
39. Landriscina A, Rosen J, Friedman 
A. Nanotechnology, inflammation 
and the skin barrier: innovative 
approaches for skin health and 
cosmesis. Cosmetics 2015; 2(2):177-
86.
https://doi.org/10.3390/cosmetics2020177 
40. Marin E, Briceno M, George CC. 
Method to produce curcumin oil-in-
water nanoemulsions as templates 
for drug carriers. J Biotechnol 
Biomater 2016; 06:1-8.
h t t p s : / / d o i . o r g / 1 0 . 4 1 7 2 / 2 1 5 5 -
952X.1000247 
41. Danole A, Kothali B, Apte A, Kulkarni 
A, Khot V, Patil A. Nanoparticles: an 
overview. Am J Pharmtech Res 2015; 
5:1-31.
42. Roberts M, Mohammed Y, Pastore M, 
Namjoshi S, Yousef S, Alinaghi A, et 
al. Topical and cutaneous delivery 
using nanosystems. J Control Release 
2017; 247:86-105.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
jconrel.2016.12.022 
43. Dhanasekaran HR, Sharma 
CP, Haridoss P. Drug delivery 
nanosystems: an introduction. 
In: Sharma, editor. Drug Delivery 
Nanosystems for Biomedical 
Applications [Internet]. Elsevier; URL: 
https://linkinghub.elsevier.com/
retrieve/pii/B9780323509220000018, 
2018 [cited 2020 Jan 8]. p. 1–12.
44. Wu X, Guy RH. Applications of 
nanoparticles in topical drug 
delivery and in cosmetics. J Drug 
Deliv Sci Technol 2009; 19(6):371-84. 
45. Nastiti C, Ponto T, Abd E, Grice 
J, Benson H, Roberts M. Topical 
nano and microemulsions for skin 
delivery. Pharm 2017; 9(4):37.
h t t p s : / / d o i . o r g / 1 0 . 3 3 9 0 /
pharmaceutics9040037 
46. Purohit DK, Nandgude TD, Poddar 
SS. Nano-lipid carriers for topical 
application: current scenario. Asian 
J Pharm 2016; 9(5):s1-9. 
47. Benson HAE, Mohammed Y, Grice 
JE, Roberts MS. Formulation effects 
on topical nanoparticle penetration. 
In: Hamblin M, Avci P, Prow T, 




2016 [cited 2019 Sep 8]. p. 115–26.
48. Guglielmini G. Nanostructured novel 
carrier for topical application. Clin 
Dermatol 2008; 26(4):341-6.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
clindermatol.2008.05.004 
49. Shakeel F, Shafiq S, Haq N, Alanazi 
FK, Alsarra IA. Nanoemulsions as 
potential vehicles for transdermal 
and dermal delivery of hydrophobic 
compounds: an overview. Expert 
217
J Med Sci, Volume 53, Number 2, 2021 April: 206-217
Opin Drug Deliv 2012; 9(8):953-74.
https://doi.org/10.1517/17425247.201
2.696605 
50. Chellapa P, Mohamed AT, Keleb EI, 
Eid AM, Issa YS, Elmarzugi NA, et al. 
Nanoemulsion and nanoemulgel as 
a topical formulation. IOSR J Pharm 
2015; 5(10):43-7. 
51. Dhawan S, Sharma P, Nanda S. 
Cosmetic nanoformulations and 
their intended use. In: Nanda 
A, Nguyen T, Slimani Y, NandaS, 




[cited 2020 Oct 2]. p. 141–69.
52. Kaul S, Gulati N, Verma D, Mukherjee 
S, Nagaich U. Role of nanotechnology 
in cosmeceuticals: a review of 
recent advances. J Pharm 2018; 
2018:3420204.
https://doi.org/10.1155/2018/3420204 
53. Wissing SA, Müller RH. The influence 
of solid lipid nanoparticles on skin 
hydration and viscoelasticity: in vivo 
study. Eur J Pharm Biopharm 2003; 
56(1):67-72.
ht tps : / /doi .org /10 .1016/s0939-
6411(03)00040-7 
54. Berardesca E, Barbareschi M, Veraldi 
S, Pimpinelli N. Evaluation of efficacy 
of a skin lipid mixture in patients 
with irritant contact dermatitis, 
allergic contact dermatitis or atopic 
dermatitis: a multicenter study: 
evaluarion of a skin lipid mixture. 
Contact Dermatitis 2001; 45(5):280-5.
https: / /doi .org/10.1034/ j .1600-
0536.2001.450505.x 
55. Damiani G, Eggenhöffner R, Pigatto 
PDM, Bragazzi NL. Nanotechnology 
meets atopic dermatitis: current 
solutions, challenges and future 
prospects. Insights and implications 
from a systematic review of the 
literature. Bioact Mater 2019; 4:380-6.
h t t p s : / / d o i . o r g / 1 0 . 1 0 1 6 / j .
bioactmat.2019.11.003 
56. Bernardi DS, Pereira TA, Maciel NR, 
Bortoloto J, Viera GS, Oliveira GC, 
et al. Formation and stability of oil-
in-water nanoemulsions containing 
rice bran oil: in vitro and in vivo 
assessments. J Nanobiotechnol 2011; 
9(1):44.
https://doi.org/10.1186/1477-3155-9-44 
57. Nasrollahi SA, Ayatollahi A, 
Yazdanparast T, Samadi A, Hosseini 
H, Shamsipour M, et al. Comparison 
of linoleic acid-containing water-in-
oil emulsion with urea-containing 
water-in-oil emulsion in the 
treatment of atopic dermatitis: 
a randomized clinical trial. Clin 
Cosmet Investig Dermatol 2018; 
11:21-8.
https://doi.org/10.2147/CCID.S145561
